Dr. Imad Treish

Dr. Imad Treish is the Chief Strategy Officer for the King Hussein Cancer Center (KHCC). In this capacity, he is responsible for the development and implementation of KHCC’s strategic plan, and for overseeing major strategic initiatives at KHCC. During his tenure as Chief Strategy Officer, Dr. Treish has been working to expand the  local and regional outreach for KHCC and to advance KHCC’s clinical computing platforms to improve clinical outcomes, decrease resource utilization, increase patient satisfaction, and ensure seamless integration with other platforms.

Prior to this, Dr. Treish served as the Chief Operating Officer at KHCC from 2009 to 2018 during which he oversaw the operations of KHCC’s state-of-the-art, 350-bed comprehensive care center. He was an instrumental figure in the design, construction, commissioning, and operation of 84,000m2 extension which opened in September 2017. Dr. Treish is a member of KHCC’s Executive Committee, Medical Board, Pharmacy & Therapeutics Committee, and ICT Steering Committee, among others.

From 2018-2019, Dr. Treish was the Oncology Chief Operating Officer with Abraaj Capital Health Fund (Evercare), a one billion-dollar private equity fund which aims to improve lives in a number of low and middle income countries. The position oversaw the development and operation of cancer treatment facilities in India, Pakistan, Kenya and Nigeria.

Dr. Treish has extensive experience in oncology clinical pharmacy and was the founding chairman of the Department of Pharmacy in KHCC between 2002 and 2009, which was Jordan’s first modern hospital pharmacy department. He has a particular interest in the fields of cytotoxic drug safety and environmental controls to reduce cross contamination of cytotoxic drugs. In addition, Dr. Treish is a leading expert on healthcare policy particularly health economics and palliative care. Moreover, Dr. Treish is interested in cancer biomarkers and, more specifically, genomic markers of drug efficacy, toxicity, and economics.

Dr. Treish obtained his Doctor of Pharmacy from the Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill, North Carolina in 1999. He completed training in Hematology/Oncology at UNC Healthcare in North Carolina in 2000.